Clinical Trials in Slovakia

• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni… Ended
  2023-505755-40-00 Phase II Chronic kidney disease Bayer AG
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 Phase II Migraine H. Lundbeck A/S
• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended
  2023-508736-62-00 Phase II Heart failure (HF) with reduced ejection fraction (HFrEF) Cardurion Pharmaceuticals Inc.
• A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu… Ended
  2023-507268-37-00 Phase III Hereditary Angioedema Pharvaris Netherlands B.V.
• A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended
  2023-509412-28-00 Phase II Type 2 Diabetes Novo Nordisk A/S
• “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended
  2023-503289-22-00 Phase II Relapsing Multiple Sclerosis Eli Lilly & Co.
• A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended
  2023-510148-19-00 Phase II Chronic Heart Failure AstraZeneca AB
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended
  2023-508377-82-00 Phase II/III Hidradenitis Suppurativa (HS) Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended
  2023-506696-10-00 Phase III Non-Small Cell Lung Cancer F. Hoffmann-La Roche AG
• Comparison of efficacy and safety of BP05 product and product of Lucentis in patients with Wet Age related Macular Degeneration Ended
  2023-507459-31-03 Phase III wet macula degeneration Curateq Biologics Private Limited
• A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended
  2023-507640-36-00 Phase III Resistant hypertension (rHTN) defined as blood pressure that… Astrazeneca AB
• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 Phase II Chronic Kidney Disease, Type 2 diabetes Novo Nordisk A/S
• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended
  2023-506893-11-00 Phase II Cirrhosis of the liver is a condition in which the liver is … Astrazeneca AB
• REIMAGINE 3: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended
  2022-502679-43-00 Phase III Type 2 diabetes Novo Nordisk A/S
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended
  2023-504564-42-00 Phase II Moderate to Severe Rheumatoid Arthritis Anaptysbio Inc.
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 Phase III complicated urinary tract infection (cUTI) or acute pyelonep… Spero Therapeutics Inc.
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 Phase II Heart Failure Novartis Pharma AG
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 Phase III Uncontrolled hypertension (uTHN) defined as blood pressure t… Astrazeneca AB
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 Phase II Rheumatoid arthritis Sanofi-Aventis Recherche & Developpement
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 Phase II Early Alzheimer’s Disease with Biomarkers of Inflammation Inmune Bio Inc.
• A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo … Ended
  2023-506197-12-00 Phase II Dyslipidemia Dyslipidemias are alterations to the plasma lip… Astrazeneca AB
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended
  2023-503333-22-00 Phase III Moderate to severe controlled asthma according to Step 4 and… Chiesi Farmaceutici S.p.A.
• A Phase 2a Study to Evaluate Setanaxib in Patients with Alport Syndrome Ended
  2023-505292-73-00 Phase II Alport syndrome Calliditas Therapeutics Suisse S.A.
• Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended
  2023-503790-37-00 Phase III Post-Menopausal Osteoporosis Curateq Biologics Private Limited

Showing 361–384 of 478 trials